2017
DOI: 10.2174/1389557516666160907151454
|View full text |Cite
|
Sign up to set email alerts
|

Novel Antibacterial Agents: An Emergent Need to Win the Battle Against Infections

Abstract: Several advances have been made but a great effort is still mandatory in order to reach feasible, effective and marketable novel antimicrobial products.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
17
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 29 publications
(17 citation statements)
references
References 0 publications
0
17
0
Order By: Relevance
“…Instead of developing new antibiotics that address novel targets, current approaches focus on structural modifications of well-established antibiotics such as vancomycin to restore their impact on resistant bacteria. Various further strategies to combat lifethreatening bacterial infections, such as the use of bacteriophages (Matsuzaki et al 2005), monoclonal antibodies (Lorenz et al 2000;Motley et al 2019), antimicrobial peptides (Fox 2013), metallic and polymeric nanoparticles (Beyth et al 2015), and quorum-sensing inhibitors (Rasmussen and Givskov 2006), among others, are under extensive investigation (Simões et al 2017). However, despite partially suggesting promising potential as effective alternative antimicrobials, to date, none of these novel strategies have found significant broad application.…”
Section: Antibiotic Resistance -An Emerging Problemmentioning
confidence: 99%
“…Instead of developing new antibiotics that address novel targets, current approaches focus on structural modifications of well-established antibiotics such as vancomycin to restore their impact on resistant bacteria. Various further strategies to combat lifethreatening bacterial infections, such as the use of bacteriophages (Matsuzaki et al 2005), monoclonal antibodies (Lorenz et al 2000;Motley et al 2019), antimicrobial peptides (Fox 2013), metallic and polymeric nanoparticles (Beyth et al 2015), and quorum-sensing inhibitors (Rasmussen and Givskov 2006), among others, are under extensive investigation (Simões et al 2017). However, despite partially suggesting promising potential as effective alternative antimicrobials, to date, none of these novel strategies have found significant broad application.…”
Section: Antibiotic Resistance -An Emerging Problemmentioning
confidence: 99%
“…), are frequently isolated in hospital environments, where they are responsible for the majority of nosocomial infections [5]. In particular, Gram-positive bacteria have predominantly developed resistance to all the available antibiotics and pose a serious problem not only in hospitals but also for the general population [6,7]. Infections of methicillin-resistant Staphylococcus aureus (MRSA) are of particular concern [8].…”
Section: Introductionmentioning
confidence: 99%
“…Such scenario has increased the demand to explore new innovative strategies in antimicrobial therapies (Kruijshaar et al, 2008;Arias and Murray, 2009;Harms et al, 2016). Up to date, several innovative approaches that are currently under investigation are antimicrobial peptides, therapeutic antibodies, phage therapy, and antimicrobial NPs (Simoes et al, 2017). Recently, MNPs based strategies have been developed to treat infections caused by multi-drug resistant bacteria as well as bacteria-related biofilm (Reddy et al, 2012;Bohara and Pawar, 2015;Zazo et al, 2016;Häffner and Malmsten, 2017;Majid et al, 2018).…”
Section: Bacterial Theranosticsmentioning
confidence: 99%